公开(公告)号：US20230020272A1

公开(公告)日：2023-01-19

申请号：US17782734

申请日：2020-12-04

申请人： NANEXA AB

发明人： Anders JOHANSSON ,  Marten ROOTH ,  Joel HELLRUP

IPC分类号： A61K9/50 ,  A61K31/706

摘要： There is provided a process for the preparation of composition in the form of a plurality of particles having a weight-, number-, and/or volume-based mean diameter that is between amount 10 nm and about 700 μm, which particles comprise: (a) solid cores, preferably comprising a biologically active agent; and (b) two or more sequentially applied, discrete layers, each of which comprises at least one separately applied coating material, and which two or more layers together surround, enclose and/or encapsulate said cores, which process comprises the sequential steps of: (1) applying an initial layer of at least one coating material to said solid cores by way of a gas phase deposition technique; (2) discharging the coated particles from the gas phase deposition reactor and subjecting the coated particles to agitation to disaggregate particle aggregates formed during step (1) by way of mechanical sieving technique; (3) reintroducing the disaggregated, coated particles from step (2) into the gas phase deposition reactor and applying a further layer of at least one coating material to the reintroduced particles; and (1) optionally repeating steps (2) and (3) one or more times to increase the total thickness of the at least one coating material that enclose(s) said solid core. The gas phase deposition technique is preferably atomic layer deposition. When the cores comprise biologically active agent, the compositions may provide for the delayed or sustained release of said active agent without a burst effect.

公开(公告)号：US20240277749A1

公开(公告)日：2024-08-22

申请号：US18568219

申请日：2022-06-10

申请人： NANEXA AB

发明人： Anders JOHANSSON ,  Mårten ROOTH ,  Erik LINDAHL ,  Joel HELLRUP ,  David WESTBERG

IPC分类号： A61K31/706 ,  A61K9/00 ,  A61K9/10 ,  A61K9/50 ,  A61P35/00 ,  C23C16/40 ,  C23C16/455

CPC分类号： A61K31/706 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/501 ,  A61K9/5073 ,  A61P35/00 ,  C23C16/407 ,  C23C16/45555

摘要： There is provided a pharmaceutical formulation that is useful in the treatment of myelodysplastic syndrome, comprising a plurality of particles suspended in an aqueous carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 μm; and (b) comprise solid cores comprising azacitidine, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is between at least 1:6 and up to and including about 6:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of azacitidine to treat myelodysplastic syndrome without a burst effect.

公开(公告)号：US20230157968A1

公开(公告)日：2023-05-25

申请号：US17919415

申请日：2021-04-16

申请人： NANEXA AB

发明人： Anders JOHANSSON ,  Mårten ROOTH ,  Joel HELLRUP

IPC分类号： A61K9/51 ,  A61K31/706 ,  A61K9/50

CPC分类号： A61K9/5115 ,  A61K31/706 ,  A61K9/5192 ,  A61K9/501 ,  A61K9/5089 ,  A61K9/5123 ,  A61K9/0019

摘要： There is provided a pharmaceutical or veterinary formulation comprising: (a) a plurality of particles having a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 μm, which particles comprise solid cores coated with zinc oxide; suspended in (b) an oleaginous carrier system comprising a pharmaceutically-acceptable or veterinarily-acceptable oil, which zinc oxide coated particles comprise: (1) solid cores comprising a biologically-active agent; (2) one or more discrete layers surrounding said cores, said one or more layers each comprising at least one separate zinc oxide coating. Said zinc oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. When the cores comprise biologically-active agent, and the particles are suspended in an oleaginous carrier system, the formulation may provide for the delayed or sustained release of said active agent without a burst effect.

公开(公告)号：US20220307132A1

公开(公告)日：2022-09-29

申请号：US17545783

申请日：2021-12-08

申请人： Nanexa AB

发明人： Anders JOHANSSON ,  Mårten ROOTH ,  Joel HELLRUP

IPC分类号： C23C16/455 ,  A61J3/00 ,  B01J2/00 ,  B01J13/04 ,  B05B7/00 ,  C23C16/54 ,  C23C16/44

摘要： A reactor for forming fully coated particles having a solid core, the reactor comprises a reactor vessel which is configured to receive particles, and a gas phase coating mechanism that is configured to selectively introduce pulses of gas phase materials that form a coating on the particles. The reactor also includes a sieve (16) that is located within the reactor vessel, and a forcing means that is configured to force the particles through the sieve (16) in use. The sieve is configured to deagglomerate any particle aggregates formed in the reactor vessel upon forcing of the particles by the forcing means through the sieve.

公开(公告)号：US20240277624A1

公开(公告)日：2024-08-22

申请号：US18568363

申请日：2022-06-10

申请人： NANEXA AB

发明人： Anders JOHANSSON ,  Mårten ROOTH ,  Erik LINDAHL ,  Joel HELLRUP ,  Jonas FRANSSON ,  David WESTBERG ,  Otto SKOLLING

IPC分类号： A61K9/50 ,  A61K9/00 ,  A61K9/10 ,  A61K9/51 ,  A61K38/00 ,  C23C16/40 ,  C23C16/44 ,  C23C16/455

CPC分类号： A61K9/5073 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/501 ,  A61K9/5115 ,  C23C16/407 ,  C23C16/4417 ,  C23C16/45555 ,  A61K38/00

摘要： There is provided a pharmaceutical formulation that is useful in delivering a biologic active drug in a high dose, comprising a plurality of particles suspended in an aqueous carrier system, which particles: pharmaceutical formulation, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 pm; and (b) comprise solid cores comprising a biologic active drug, coated, at least in part, by a coating of inorganic material, and wherein the formulation comprises a concentration of said biologic active drug of at least 10 mg/ml. Preferred biologic active drug include immunoglobulins, monoclonal antibodies, antibody mimetics, cytokines and cytokine antagonists, and human peptide hormones.

公开(公告)号：US20230009472A1

公开(公告)日：2023-01-12

申请号：US17782564

申请日：2019-12-06

申请人： Nanexa AB

发明人： Anders JOHANSSON ,  Mårten ROOTH ,  Joel HELLRUP

IPC分类号： A61K9/28 ,  A61K9/20 ,  A61K9/00 ,  A61K47/26 ,  A61K47/54 ,  A61K31/404

摘要： There is provided a composition comprising a plurality of particles of a weight-, number-, or volume-, based mean diameter that is between amount 10 nm and about 700 µm, which particles are made up of: (a) a solid core, which solid core preferably comprises a biologically active agent; (b) one or more discrete layers surrounding said core, said one or more layer s each comprising at least one separate coating material; and (c) a final overcoating layer of a coating material, which overcoating layer surrounds, encloses and/or encapsulates said core and said previously-applied layers of coating material, and which final layer is of a thickness that is less than said previously-applied layers. Said layers (b) and (c) are preferably applied by way of a gas phase coating technique, such as atomic layer deposition. When the cores comprise biologically active agent, the compositions may provide for the delayed or sustained release of said active agent without a burst effect.